Join Dan Sutton, CEO Tantalus Labs, for an overview of the specific aspects related to operating in the medical cannabis space (facility standards, licensing process, production and sales quotas or limitations, time to market, etc.), various cannabis products offered, and a discussion covering the heightened activity in the cannabis market.  With certain public cannabis companies performing significant acquisitions in recent months, Dan will provide his take on the “inflated” valuations of marijuana public companies and the potential impact of say “Big Tobacco” or “Big Pharma” entering the cannabis industry with their significantly larger R&D budgets.  He will also discuss the impact of the legalization of recreational marijuana in Canada come July 2018, as it seems there are varying market forecasts and perspectives of the potential impacts on adjacent markets, and discuss limitations due to legal restrictions in the US vs. global opportunities.

The information, analysis and opinions expressed in the webinars, podcasts and/or congress presentations are solely those of the presenter/author, are not reviewed by the Institute as to content or accuracy, and are not endorsed by CBV Institute or any of its Members.